Nov. 12 at 7:37 PM
$CRDL Deep-value biotech flying under the radar. CardiolRx in Phase 3 for recurrent pericarditis: Phase 2 showed pain reduced by 64%, CRP by 95%. Oral, safe, and five times cheaper than
$KNSA’s Arcalyst. Also targeting acute myocarditis—no FDA-approved therapies exist. CRD-38, a subcutaneous cannabidiol formulation, is in preclinical development for heart failure and has demonstrated strong cardioprotective effects. Following two financings in October, cash now exceeds
$22M, extending the runway through end of 2027. No debt, clean cap structure. Management confirmed ongoing discussions with major tech and pharma firms around AI and cardiac imaging collaborations. Total addressable market across lead indications is estimated above
$1.7B. Five independent analysts issued price targets ranging from
$6 to
$11, while the current share price remains at
$1. With strong trial execution, late-stage catalysts, and strategic positioning, Cardiol may be nearing a critical value inflection point.
